10-Q: Canopy Growth Narrows Losses, Boosts Cash, Resolves Going Concern Doubts

Canopy Growth reported significantly reduced net losses and improved cash flow, resolving prior going concern doubts, driven by strategic debt reduction and strong Canadian cannabis sales.

Summary

• Net loss from continuing operations for the three months ended September 30, 2025, significantly improved to $1.6 million, compared to a loss of $131.6 million in the prior year.
• Adjusted EBITDA loss for the three months ended September 30, 2025, decreased to $3.0 million, from a loss of $5.5 million in the same period last year, primarily due to selling, general and administrative expense cost savings.
• Net revenue for the three months ended September 30, 2025, increased by 6% to $66.7 million, with Canadian adult-use cannabis revenue growing 30% and Canadian medical cannabis revenue increasing 17%.
• Cash and cash equivalents surged to $298.1 million as of September 30, 2025, up from $113.8 million at March 31, 2025.
• Total debt outstanding decreased to $228.2 million as of September 30, 2025, from $304.1 million at March 31, 2025, following significant prepayments on the Credit Facility and full settlement of Supreme Debentures.
• The company has resolved conditions that previously raised substantial doubt about its ability to continue as a going concern.
• Canopy USA, a U.S.-domiciled holding company, has completed acquisitions of Wana (100%), Acreage (100%), and approximately 77% of Jetty, positioning the company for future U.S. market entry upon regulatory permissibility.

Sentiment

Score: 7

Explanation: The company demonstrated significant improvements in net loss, Adjusted EBITDA, and cash position, successfully resolving previous going concern doubts. Strategic debt reduction and ongoing capital raises bolster liquidity. While gross margins declined due to product mix and international challenges, the overall financial health shows a positive trajectory. However, ongoing legal/regulatory risks and market uncertainties temper a higher score.

Positives

• Net loss from continuing operations dramatically improved by $129.9 million for the three months ended September 30, 2025, to $1.6 million.
• Adjusted EBITDA loss decreased by $2.5 million to $3.0 million for the three months ended September 30, 2025, indicating improved operational efficiency.
• Cash and cash equivalents increased substantially to $298.1 million as of September 30, 2025, from $113.8 million at March 31, 2025, bolstering liquidity.
• Total debt outstanding decreased by $75.9 million to $228.2 million, reflecting successful deleveraging efforts including significant Credit Facility prepayments and full settlement of Supreme Debentures.
• The company has formally concluded that it has sufficient liquidity to meet short-term obligations, resolving previous 'going concern' doubts.
• Canadian adult-use cannabis net revenue grew by 30% to $23.9 million, driven by new product offerings like infused pre-rolled joints and All-In-One vaporizers.
• Canadian medical cannabis net revenue increased by 17% to $21.8 million, attributed to more insured customers, larger order sizes, and expanded product choices.
• Selling, general and administrative expenses decreased by 13% to $36.3 million for the three months ended September 30, 2025, due to headcount reductions and lower third-party costs.
• Loss on asset impairment and restructuring significantly reduced to $0.5 million from $20.8 million in the prior year, indicating fewer large-scale restructuring events.

Negatives

• Gross margin percentage declined to 33% for the three months ended September 30, 2025, from 35% in the prior year, primarily due to lower international cannabis sales and higher inventory provisions.
• International markets cannabis revenue decreased by 39% to $5.1 million for the three months ended September 30, 2025, due to supply chain challenges in Europe.
• Storz & Bickel revenue decreased by 10% to $15.8 million for the three months ended September 30, 2025, attributed to strong prior-year sales and continued consumer economic uncertainty.
• Interest income decreased by $0.4 million for the three months ended September 30, 2025, due to lower interest rates.
• Adjusted EBITDA loss for the six months ended September 30, 2025, slightly increased to $11.0 million from $10.8 million in the prior year, due to softer gross margins across the business.

Risks

• Uncertainty regarding the application of U.S. state and federal law to cannabis and hemp products, and the scope of regulation by U.S. federal agencies.
• Potential for future impairment losses, including write-downs of intangible assets and goodwill.
• Ability to refinance debt on favorable terms and comply with covenants in debt facilities and instruments.
• The Trust's future ownership interest in Canopy USA is not quantifiable, and the Trust may have significant ownership and influence over Canopy USA.
• Risks that Acreage may not satisfy its debt obligations as they become due.
• Volatility in and/or degradation of general economic, market, industry, or business conditions, including inflation, interest rates, and trade policy.
• Compliance with applicable environmental, economic, health and safety, energy, and other policies and regulations, particularly health concerns with vaping and cannabis products.
• Risks relating to inventory write-downs.
• Ongoing putative class action lawsuits alleging misrepresentations in company disclosures and failure to remedy internal control deficiencies.
• Ongoing SEC investigation related to financial reporting matters of the BioSteel business unit, with potential for material adverse impact from remedial measures, sanctions, fines, or penalties.
• A counterclaim seeking $6.4 million in general damages and $1.0 million in aggravated damages has been commenced against the company in a private arbitration.
• A new putative class action in the U.S. District Court alleges the company overstated cost reduction efficacy and gross margin health, and downplayed issues with Claybourne pre-rolled joints and Storz & Bickel vaporizer device costs.
• The proposed 2025 Canadian federal budget, if passed, could adversely affect the company's profitability and medical cannabis revenues by decreasing the reimbursement rate for eligible RCMP members and veterans from $8.50 per gram to $6.00 per gram.

Future Outlook

The company anticipates capitalizing on growth opportunities in the U.S. cannabis sector through Canopy USA, with expectations for the final tranche closing of the Jetty acquisition and potential issuance of additional common shares for Wana and Jetty payments. The timing and nature of legislative changes in the U.S. regarding cannabis regulation are key factors. The company will perform its next annual goodwill impairment analysis on March 31, 2026. The outcome of the proposed 2025 Canadian federal budget, particularly the medical cannabis reimbursement adjustment, is expected to impact future medical cannabis revenues and profitability.

Management Comments

• We conclude that we have sufficient liquidity to meet our short-term obligations, resolving the conditions that previously raised substantial doubt about our ability to continue as a going concern, based on our cash and cash equivalents of $298.1 million and current portion of long-term debt of $1.8 million as of September 30, 2025, along with financing actions taken and projected future cash flows.
• Management believes that Adjusted EBITDA provides meaningful and useful financial information, as this measure demonstrates the operating performance of businesses.

Industry Context

Canopy Growth operates in the global cannabis market, with core operations in Canada (adult-use and medical), Europe, and Australia. The company is strategically positioned for the U.S. cannabis market through its non-controlling interest in Canopy USA, which holds significant U.S. cannabis assets (Wana, Jetty, Acreage, TerrAscend), pending U.S. federal regulatory changes. The Canadian market shows growth in specific product categories like infused pre-rolls and vaporizers. However, the European market faces supply chain challenges, and the Storz & Bickel segment is affected by consumer economic uncertainty. The proposed Canadian federal budget's potential reduction in medical cannabis reimbursement rates highlights evolving regulatory pressures in key markets.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking. The analysis focuses on internal performance metrics and year-over-year changes within the company's own segments.

Management Changes

Corporate Governance

Legal Proceedings

• An ongoing putative class action (Dziedziejko v. Canopy Growth Corporation et al.) in Ontario alleges misrepresentations in company disclosures and failure to remedy internal control deficiencies, seeking unspecified damages.
• A putative class action (Asmaro v. Canopy Growth Corporation et al.) in British Columbia alleges misrepresentations in company disclosures and seeks unspecified damages.
• The company is subject to an ongoing SEC investigation related to financial reporting matters of the BioSteel business unit, following a voluntary self-report.
• A payment guarantor commenced a counterclaim against the company in a private arbitration, seeking $6,399,700 in general damages and $1,000,000 in aggravated damages for alleged breaches of a share purchase agreement.
• A putative class action (Baron v. Canopy Growth Corporation et al.) in the U.S. District Court for the Eastern District of New York alleges violations of U.S. federal securities laws, claiming the company overstated cost reduction efficacy and gross margin health, seeking unspecified damages.

Related Party Transactions

• The Elevate loan, previously an intercompany loan, is now considered a related party loan and recognized at fair value in the consolidated financial statements following the deconsolidation of Canopy USA. As of September 30, 2025, the aggregate principal and interest amount owing to Canopy Growth is $240,432,000 (US$172,711,000) and $63,493,000 (US$45,610,000), respectively.
• Canopy USA delivered guarantees in respect of the obligations owing pursuant to the Elevate loan receivable on December 9, 2024, which are factored into its fair value consideration.

Stakeholder Impact

• Shareholders: Significant reduction in net loss and resolution of 'going concern' doubts are positive for shareholder confidence. Ongoing ATM programs dilute existing shares but provide necessary capital. Legal proceedings and regulatory investigations pose potential financial and reputational risks.
• Employees: Continued reductions in headcount as part of cost-saving measures, and employee restructuring costs, indicate ongoing workforce adjustments. Share-based compensation expense was impacted by executive departures.
• Customers (Canadian Adult-Use & Medical): Increased product offerings and improved order sizes for medical customers are positive. Potential price increases or reduced access for RCMP and VAC medical cannabis users due to proposed budget changes could negatively impact this segment.
• Creditors: Significant debt reduction and improved liquidity strengthen the company's ability to meet its obligations, as evidenced by Credit Facility prepayments and full settlement of Supreme Debentures.
• Suppliers: No specific impact mentioned, but overall financial stability and reduced operating expenses could lead to more stable relationships.

Next Steps

• Canopy USA to complete the final tranche closing in connection with the acquisition of Jetty.
• Canopy Growth may issue additional common shares to satisfy deferred and/or option exercise payments to Wana and Jetty shareholders.
• Canopy USA may acquire additional Canopy USA Common Shares in connection with the Trust Transaction.
• The Canadian House of Commons is expected to vote on the 2025 Budget in November 2025, which includes a proposed medical cannabis reimbursement adjustment.
• The company is required to perform its next annual goodwill impairment analysis on March 31, 2026.
• Continue to review and pursue selected external financing sources, including public offerings of equity and debt securities, and debt financing with more favorable terms.
• Potentially retire outstanding debt through cash purchases, exchanges for equity securities, or open market purchases.

Key Dates

Recommendation

The filing demonstrates a strong turnaround in Canopy Growth's financial health, marked by a dramatic reduction in net loss and Adjusted EBITDA loss, and a substantial increase in cash and cash equivalents. The resolution of the 'going concern' doubt is a critical positive, signaling improved financial stability. Strategic debt reduction efforts have significantly strengthened the balance sheet. While gross margins have seen some compression, the company's core Canadian cannabis segments are showing robust growth, and its strategic positioning in the nascent U.S. cannabis market through Canopy USA offers significant long-term upside potential. Despite ongoing legal and regulatory uncertainties, the overall trajectory indicates a company on a path to improved profitability and sustained operations, making it an attractive 'buy' for investors with a medium to long-term horizon and an appetite for growth in the evolving cannabis sector.

Keywords

Cannabis, Marijuana, Storz & Bickel, Vaporizers, SEC Filing, 10-Q, Financial Results, Earnings, Liquidity, Debt Reduction, Canopy USA, Acreage, Wana, Jetty, TerrAscend, ATM Program, Canada Cannabis, Medical Cannabis, Adult-Use Cannabis, Adjusted EBITDA, Going Concern, Regulatory Risk, Litigation